The effects of fluid resuscitation on the hemodynamic parameters of experimental induced endotoxemia in the neonatal calves

Akyüz, Enes; Coşkun, Alparslan; Şen, İsmai̇l

doi:10.15312/eurasianjvetsci.2016422396

Cited by 6 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are consistent with those obtained in other studies of the treatment of sepsis in calves using various therapeutic agents [ 4 , 28 ]. Similar results have been reported in previous studies [ 1 , 6 ]. These results indicate that LPS treatment can mimic endotoxemia.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy

Altan

Üney

et al. 2017

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

The aim of this research was to compare plasma pharmacokinetics of ceftiofur sodium (CS) in healthy calves, and in calves with experimentally induced endotoxemia. Six calves received CS (2.2 mg/kg, IM) 2 hr after intravenous administration of 0.9% NaCl (Ceft group). After a washout period, the same 6 calves received CS 2 hr after intravenous injection of lipopolysaccharide (LPS+Ceft group). Another group of 6 calves received a combination of drug therapies that included CS 2 hr after administration of 0.9% NaCl (Comb group). A third group of 6 calves received the same combination therapy regimen 2 hr after intravenous injection of lipopolysaccharide (LPS+Comb group). Plasma concentrations of CS and all desfuroylceftiofur-related metabolites were determined using HPLC, and its pharmacokinetic properties were determined based on a two-compartment model. The peak concentration of CS in the LPS+Comb group occurred the earliest, and the clearance rate of CS was the highest in the Comb and LPS+Comb groups (P<0.05). The elimination half-life of CS in the LPS+Ceft group was longer than that in the Ceft and Comb groups (P<0.05). The results of this study indicate that combined therapies and endotoxemic status may alter the plasma pharmacokinetics of CS in calves.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Exposed calves can exhibit sepsis-related symptoms. The primary aims in treating sepsis in calves should be controlling infection, regulating the inflammatory response, replacing fluids, managing circulatory tension and relieving stress [ 1 , 4 , 5 , 41 ].…”

mentioning

confidence: 99%

Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy

Altan

Üney

et al. 2017

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

show abstract

“…Diarrhea caused by Escherichia coli (E. coli), cryptosporidium, rotavirus, and coronavirus is more common in calves during the first four weeks of life (Lorenz et al 2011). Serious complications caused by E.coli can lead to death (Constable, 2007;Akyüz et al 2016). Infectious agents that cause diarrhea are usually taken orally.…”

Section: Introductionmentioning

confidence: 99%

Neopterin, procalcitonin, clinical biochemistry, and hematology in calves with neonatal sepsis

Akyüz

Gökçe

2021

Trop Anim Health Prod

View full text Add to dashboard Cite

This study aims to determine how neopterin, procalcitonin, biochemical and hematological parameters change during treatment of calves with neonatal sepsis. A total of 25 calves divided into two groups. Sepsis group was composed of 15 newborn calves aged 0–10 days which met neonatal sepsis criteria, but did not receive any treatment. Control group included 10 healthy calves aged 0–10 days. Clinical examinations (respiratory rate, rectal temperature, heart rate, capillary refill time, sucking reflex) were performed at certain times before (0th h) and during (12th, 24th, 48th, and 72th h) the treatment. The blood was taken from the jugular vein from the sepsis group before (0th h) and during the treatment (12th, 24th, 48th, and 72nd h) and once from the control group. Procalcitonin pretreatment (0th h) and control group concentrations were found as 178.08 ± 2.4 (pg/mL) and 42.78 ± 1.25 (pg/mL), respectively ( p < 0.001). Neopterin pretreatment (0th h) and control group concentrations were determined as 14.44 ± 0.30 (ng/mL) and 3.63 ± 0.29 (ng/mL), respectively ( p < 0.001). As a result, neopterin and procalcitonin concentration decreased along with the treatment, confirming the presence of sepsis in calves and suggesting that sepsis could be a prognostic indicator. Therefore, both procalcitonin and neopterin can be prognostic and diagnostic in calves with sepsis.

show abstract

“…It has been reported that E. coli endotoxin‐induced fever reduces V dss of marbofloxacin in goats (Waxman et al, 2003) and V dss of enrofloxacin in rabbits (Elmas et al, 2006). Fluid therapy and dexamethasone have positive effects on hemodynamic changes and membrane permeability during endotoxemia (Akyuz, Coskun, & Sen, 2016; Ferguson, Dirikolu, & Hoenig, 2009). In the present study, the reason why V dss remained unchanged in marbofloxacin in the MBX + ST + LPS group may be because of low binding of marbofloxacin to plasma proteins or because of the positive effect of dexamethasone and fluid treatment on permeability and hemodynamic parameters.…”

Section: Discussionmentioning

confidence: 99%

Effect of supportive therapy on the pharmacokinetics of intravenous marbofloxacin in endotoxemic sheep

Coşkun

Çorum

Yazar

2020

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The purpose of this study was to determine the influences of supportive therapy (ST) on the pharmacokinetics (PK) of marbofloxacin in lipopolysaccharide (LPS)‐induced endotoxemic sheep. Furthermore, minimum inhibitory concentration (MIC) of marbofloxacin against Escherichia coli, Mannheimia haemolytica, Pasteurella multocida, Klebsiella pneumoniae, Salmonella spp., and Staphylococcus aureus was determined. The study was performed using a three‐period cross PK design following a 15‐day washout period. In the first period, marbofloxacin (10 mg/kg) was administered by an intravenous (IV) injection. In the second and third periods, marbofloxacin was co‐administered with ST (lactated ringer + 5% dextrose + 0.45% sodium chloride, IV, 20 ml/kg, dexamethasone 0.5 mg/kg, SC) and ST + LPS (E. coli O55:B5, 10 µg/kg), respectively. Plasma marbofloxacin concentration was measured using HPLC‐UV. Following IV administration of marbofloxacin alone, the t1false/2λz, AUC0–∞, ClT, and Vdss were 2.87 hr, 34.73 hr × µg/ml, 0.29 L hr−1 kg−1, and 0.87 L/kg, respectively. While no change was found in the MBX + ST group in terms of the PK parameters of marbofloxacin, it was determined that the ClT of marbofloxacin decreased, AUC0–∞ increased, and t1false/2λz and MRT prolonged in the MBX + ST + LPS group. MIC values of marbofloxacin were 0.031 to >16 µg/ml for E. coli, 0.016 to >16 µg/ml for M. haemolytica, 0.016–1 µg/ml for P. multocida, 0.016–0.25 µg/ml for K. pneumoniae, 0.031–0.063 µg/ml for Salmonella spp., and 0.031–1 µg/ml for S. aureus. The study results show the necessity to make a dose adjustment of marbofloxacin following concomitant administration of ST in endotoxemic sheep. Also, the PK and pharmacodynamic effect of marbofloxacin needs to be determined in naturally infected septicemic sheep following concomitant administration of single and ST.

show abstract

The effects of fluid resuscitation on the hemodynamic parameters of experimental induced endotoxemia in the neonatal calves

Cited by 6 publications

References 3 publications

Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy

Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy

Neopterin, procalcitonin, clinical biochemistry, and hematology in calves with neonatal sepsis

Effect of supportive therapy on the pharmacokinetics of intravenous marbofloxacin in endotoxemic sheep

Contact Info

Product

Resources

About